Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
PrECOG, LLC.
Ono Pharmaceutical Co. Ltd
MedImmune LLC
Jonsson Comprehensive Cancer Center
AstraZeneca
City of Hope Medical Center
Cedars-Sinai Medical Center
AstraZeneca
AstraZeneca
AstraZeneca
EMD Serono
AstraZeneca
AstraZeneca
Merus B.V.
Memorial Sloan Kettering Cancer Center